Spanish drugmaker Almirall (BME: ALM) left investors less than impressed with its latest financial results.
The Barcelona-based dermatology specialist was trading 4% lower on Thursday afternoon, following the presentation of the company’s figures from the first nine months of 2023.
"As we gear up for the lebrikizumab launch, we're embarking on a transformative journey for our company"Net sales for this period reached 674.6 million euros ($721.1 million), a rise of more than 6%, while total earnings before interest, taxes, depreciation and amortization (EBITDA) were 137.8 million euros, down 6% but in line with expectations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze